Navigation Links
BioFuel Energy Reports Third Quarter Results
Date:11/10/2010


(0.75)

$
(0.87)Weighted average shares outstanding-basic and diluted

25,449

24,39725,411

23,418 Additional operational data  Ethanol sold (gallons, in thousands)

56,185

51,557167,733

162,568Dry distillers grain sold (tons, in thousands)

131.3

117.3377.4

360.8Wet distillers grain sold (tons, in thousands)

65.5

84.3266.3

283.1Average FOB price of ethanol sold (per gallon)

$
.84

$
.56$
.64

$
.54Average FOB price of dry distillers grain sold (per ton)

$
88.10

$
84.25$
92.72

$
8.05Average FOB price of wet distillers grain sold (per ton)

$
22.26

$
23.08$
22.80

$
34.34Average corn cost (per bushel)

$
3.83

$
3.14$
3.65

$
3.58September 30,December 31, Summary Balance Sheet  20102009 Cash and equivalents

$
,895

$
,109 Accounts receivable

21,442

23,745 Inventories

19,159

20,885 Prepaid expenses

1,937

2,529 Other current assets

1,995

325 Property, plant and equipment, net

266,364

284,362 Debt issuance costs, net

5,320

6,472 Other non-current assets

2,591

2,348 Total assets

$
329,703

$
346,775 Total current liabilities

$
46,428

$
40,830 Long-term debt, net of current portion

218,377

220,754 Tax increment financing, net of current portion

5,527

5,591 Other non-current liabilities

4,277

1,705 Total liabilities

274,609

268,880 BioFuel Energy Corp. stockholders' equity

54,826

72,235 Noncontrolling interest

268

5,660 Total equity

55,094

77,895 Total liabilities and equity  

$
329,703

$
346,775 Total shares outstanding at November 8, 2010 (a)

32,577,713
'/>"/>

SOURCE BioFuel Energy Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
2. Algenol Biofuels Appoints Chief Science Officer
3. Ceres Trials Energy Crops at Georgia Biofuel Facility
4. Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association
5. Algenol Biofuels Further Strengthens Team With Key Appointments
6. New Bill to Expand Promotion of Biofuels Is a Welcome Boost for U.S.-Brazil Relations According to Brazilian Sugarcane Industry
7. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
8. Can Algae Biofuels Satisfy the World's Growing Biofuel Needs? Upcoming Webinar Shares the Latest Commercialization Strategies and Challenges
9. Digesting the termite digestome -- a way to make biofuels?
10. New Generation Biofuels CEO to Present at the Rodman & Renshaw Annual Global Investment Conference
11. New Generation Biofuels Announces Test Burn Agreement With Progress Energy Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... San Diego , CA (PRWEB) , ... July ... ... Biopharma, announced the successful completion of a field clinical study of its canine ... being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Enable CyberKnife Centers ... Demand for Radiosurgery, SUNNYVALE, Calif., Sept. 22 ... the field of radiosurgery,announced today that Oklahoma CyberKnife LLC, ... reduced treatment,planning and delivery times over the last two ...
... announced today,that its lead product ATIR(TM) has been ... Agency (EMEA) for the prevention of acute,Graft versus ... "Following the orphan drug designation granted by ... another important milestone in the development of,ATIR(TM) as ...
... China indicates that genetically modified cotton, altered to express the ... but also reduces pests among other nearby crops that have ... new ideas for controlling pests and maximizing crop yields in ... the journal Science on Friday, 19 September. ...
Cached Biology Technology:Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 2Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 3Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 4EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation 2GM crops protect neighbors from pests 2
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... The first study to analyze the complex ingredients in ... that these pop-into-the-mouth replacements for cigarettes in places where ... diseases and other problems. The report appears in ACS,s ... John V. Goodpaster and colleagues point out that the ...
... Mass. (March 16, 2011) Renowned cancer researchers Robert ... Hanahan, Director of the Swiss Institute for Experimental Cancer ... of Cancer," which has influenced the study of cancer ... decade. Published in January 2000, their original work, ...
... way the parasite that causes malaria reproduces could lead ... the disease. Scientists studying the disease have found ... from transmitting from person to person. Researchers at ... at a stage of its development in which it ...
Cached Biology News:New 'dissolvable tobacco' products may increase risk of mouth disease 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3
...
Mouse Cell Line Slides...
Human Cell Line Slides...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: